Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEED: Pegfilgrastim for prevention of febrile neutropenia in TPF therapy for head and neck squamous cell carcinoma
jRCTs031220695Phase 2Active, not recruiting
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Percentage of febrile neutropenia incidence by the end of one course of TPF therapy. Started Jul 2023; status: active, not recruiting.
02
Drugs
pegfilgrastim
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCTs031220695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220695.